Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

 Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

Eli Lilly Pauses Enrollment in ACTIV-3 Clinical Trial Due to Safety Concerns

Shots: 

  • The independent DSMB recommended pausing the enrollment of the ACTIV-3 clinical trial. The trial is evaluating Lilly’s bamlanivimab (LY-CoV555, 7000mg) + remdesivir as a treatment for COVID-19 in hospitalized patients, and is sponsored by the NIAID
  • Lilly trusts the judgment & supports independent DSMB decisions to exercise caution in ensuring the safety of the patients participating in the study. DSMB also considered the impact of the ACTIV-3 study pause on ACTIV-2 and did not recommend any changes to that study’s design or enrollment
  • Lilly is testing both single Ab therapy, as well as combinations of Abs as potential therapeutics for COVID-19, across two different patient populations in P-II BLAZE-1, P-III BLAZE-2, and ACTIV-2 study. These trials are not affected by the enrollment pause in the ACTIV-3 clinical trial

Click here ­to­ read full press release/ article | Ref: Eli Lilly | Image: Eli Lilly

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post